Evaluation of the combination of docetaxel/carboplatin in patients with metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN): A Southwest Oncology Group phase II study

Wolfram E. Samlowski, James Moon, J. Philip Kuebler, Craig R. Nichols, David R Gandara, Howard Ozer, Stephen K. Williamson, James N. Atkins, David E. Schuller, John F. Ensley

Research output: Contribution to journalArticle

27 Scopus citations


Carboplatin/docetaxel chemotherapy was evaluated in advanced squamous cell carcinoma of the head and neck (SCCHN). Eligibility included patients with recurrent, persistent, or metastatic SCCHN with Zubrod performance status 0-2. Docetaxel 65 mg/m2 and carboplatin (AUC of 6) were given IV in a 21-day cycle to 68 patients. Response probability was 25 percent (95%CI: 15-38). The major toxicity observed was neutropenia, with 36 patients (61 percent) experiencing Grade 3 or worse. Median progression-free survival was 3.8 months (95%CI, 3.1-4.8) Median overall survival was 7.4 months (95%CI, 6.2-8.9). The results of this study suggest this regimen is active for outpatient treatment of recurrent SCCHN patients with good performance status.

Original languageEnglish (US)
Pages (from-to)182-188
Number of pages7
JournalCancer Investigation
Issue number3
StatePublished - Apr 2007



  • Carboplatin
  • Chemotherapy
  • Docetaxel
  • Head and neck cancer
  • Taxane

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this